Telomir Pharmaceuticals, Inc.

Jupiter Neurosciences, Inc.

In mid-September, the startup Retro Biosciences, supported by OpenAI CEO Sam Altman, <a href="https://www.businessinsider.com/retro-biosciences-sam-altman-antiaging-brain-pill-longevity-healthspan-2025-9">announced</a> that this year it would begin clinical trials of its first development - a pill to "clean" the brain and fight Alzheimer's disease. Achieving longevity or even immortality is one of mankind's oldest aspirations, which is still relevant today. Silicon Valley techno-investors are pouring billions into researching ways to extend life. What are they betting on?

Silicon Valley tycoons are betting on rejuvenation. Is it possible to make money on it? 

How to invest in pharmaceutical and biotech companies? Why, despite many scientific breakthroughs and sales hits such as Ozempic or Wegovy, does the pharmaceutical sector lag behind the technology sector in capitalization growth? What companies and products should an average investor follow and what mistakes should he avoid - these and other questions were answered by Ilya Yasny, co-founder of LanceBio Ventures, a fund specializing in biotechnology and investments in the pharmaceutical industry, in a video interview for the program "Oninvest: What's Next".

Ilya Yasny: "It is easy to lose a lot of money on investments in biotech companies"

Novo Nordisk A/S

Eli Lilly and Company

Novo Nordisk's Ozempic has shown to reduce the risk of heart attack, stroke and death in patients with diabetes and cardiovascular disease

Novo drug outperformed its Eli Lilly counterpart in trials. Time to buy stock?

Altimmune, Inc.

Terns Pharmaceuticals, Inc.

Viking Therapeutics, Inc.

Following the meteoric success of Novo Nordisk and Eli Lilly’s semaglutide-based weight-loss injections, the obesity and metabolic disease treatment sector has drawn heightened investor attention. Since Ozempic was <a href="https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-ozempic-semaglutide-injection-for-the-treatment-of-adults-with-type-2-diabetes-300567052.html">approved</a>&nbsp;in December 2017, Novo Nordisk’s stock has gained 125%, pushing its <a href="https://companiesmarketcap.com/novo-nordisk/marketcap/">market capitalization</a> to $252 billion. Eli Lilly, after launching <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-Zepboundtm-tirzepatide-chronic-weight">Zepbound</a>&nbsp;in November 2023, has seen its share price climb 23% and its <a href="https://companiesmarketcap.com/eli-lilly/marketcap/">market cap</a> reach $681 billion. Morgan Stanley <a href="https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth#:~:text=Morgan%2520Stanley%2520Research%2520now%2520estimates,about%2520%252415%2520billion%2520in%2520sales">estimates</a>&nbsp;the global market for obesity drugs could exceed $150 billion by 2035.

Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market

While raising the recommendation to "buy", investment bank Berenberg simultaneously lowered the target on Novo securities by 25%

The oldest bank in Germany has bet on Novo Nordisk. How is it better than market favorite Eli Lilly?

Hansoh Pharmaceutical Group Company Limited

Hangzhou Tigermed Consulting Co., Ltd

Investors were taking profits after quotations in the sector doubled since the beginning of 2025

China's biotech stocks post worst collapse in 5 months due to possible U.S. restrictions

The Danish pharma company also lowered its profit forecast for the third time this year

Novo Nordisk will cut 9,000 employees. Why do analysts believe the stock is up 60%?

Ionis Pharmaceuticals, Inc.

Quotes of biotech Ionis Pharmaceuticals jumped 35% in a single day after it announced a successful trial of a drug that reduces triglyceride levels in the blood and prevents cases of acute pancreatitis. Analysts were positive about the results. The company, which is known for its Spinraza drug for spinal muscular atrophy, could see its shares rise another 40%, according to some analysts' models.&nbsp;

Biotech Ionis Pharmaceuticals surges 35% after upbeat trial of triglyceride drug

The negative outlook for the company has already come true, an HSBC analyst thought

Wall Street's only bearish on Eli Lilly stock has changed its mind

By contrast, the shares of Eli Lilly's competitor, Ozempic manufacturer Novo Nordisk, fell 4%

Eli Lilly's weight loss pill has passed one of the key phases of testing. Shares rose

Side effects of Viking's obesity pill upset investors

Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?

Wegovy is first-in-class approved for the treatment of liver disease, but its exclusivity is threatened by US-based Eli Lilly

Pharmaceutical Companies